A5014363979- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Caveolin-1 and cellular processes
- Esophageal Cancer Research and Treatment
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Bone health and treatments
- Lymphoma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Breast Implant and Reconstruction
- Biosimilars and Bioanalytical Methods
- Genetic factors in colorectal cancer
- DNA Repair Mechanisms
Deutsches Archäologisches Institut, Zentrale
2016-2025
Evangelisches Krankenhaus Bethesda Mönchengladbach
2015-2024
University Hospital Cologne
2009-2024
German Breast group
2008-2024
Breast Center
2010-2024
Heinrich Heine University Düsseldorf
2005-2023
Women‘s Healthcare Group
2014-2023
University of Cologne
2007-2023
Bethesda Hospital
2013-2023
Brustzentrum Klinik St. Anna
2023
Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged a powerful strategy for cancer therapy. We show that T-DM1 is particularly effective in eliciting antitumor immunity patients early breast (WSG-ADAPT trial) and HER2-expressing orthotopic tumor model. In latter, despite primary resistance to immunotherapy, combined treatment anti-CTLA-4/PD-1 (cytotoxic T lymphocyte-associated protein-4/programmed cell death protein-1)...
The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only few prospective outcome results have been available so far. In the phase III PlanB trial, RS was prospectively used to define subset of patients who received endocrine therapy. We present 3-year data and concordance analysis (among biomarkers/RS).Central tumor bank established from (intermediate high-risk, locally human epidermal growth factor...
The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating prognostic value RS, Ki-67, and other traditional clinicopathological parameters. A central tumour bank was prospectively established within PlanB. Following an amendment, hormone receptor (HR)+ , RS ≤ 11 were...
To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) guide systemic in early breast cancer.Baseline postendocrine Ki67 (Ki67post) were evaluated centrally. In trial, all patients received exclusively ET: with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved nodes) entered control arm if RS...
Importance Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, non-Hispanic Black women, and risk of progression to metastatic cancer, devastating sequela 12- 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative was chemotherapy after surgery. However, it not known whether the addition immune therapy postsurgery would be beneficial. Objective To evaluate form atezolizumab postoperative patients high-risk...
Purpose Human epidermal growth factor receptor 2 (HER2)–positive/hormone (HR)–positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little known about the efficacy of combination endocrine therapy (ET) trastuzumab or potent antibody-cytotoxic, anti-HER2 compound emtansine (T-DM1) without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted...
PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment human epidermal growth factor receptor 2–negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more following: pT greater than 2, grade 2 3, high urokinase-type plasminogen activator/plasminogen activator...
Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results higher pCR rates uncertain survival impact. We evaluated gemcitabine a backbone as short 12-week A-free focus on early response.Patients TNBC (estrogen receptor/progesterone receptor < 1%, human epidermal growth factor 2-negative,...
Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial continuous improvement of outcome has been achieved over the past decades. Response to therapy currently not considered procedure. ADAPT one first new generation (neo)adjuvant trials dealing with individualization early breast cancer aims...
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
Invasive lobular carcinoma (ILC) is the second most frequent type of breast cancer (BC) and its peculiar morphology mainly driven by inactivation CDH1, gene coding for E-cadherin cell adhesion protein. ILC-specific therapeutic disease-monitoring approaches are gaining momentum in clinic, increasing importance accurate ILC diagnosis. Several essential desirable morphological diagnostic criteria currently defined World Health Organization, routine use immunohistochemistry (IHC) not...
<b><i>Introduction:</i></b> Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Cancer provides updated state-of-the-art recommendations for early metastatic breast cancer. <b><i>Methods:</i></b> The evidence-based treatment cancer have been released in March 2024. <b><i>Results Conclusion:</i></b> This...